Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the united kingdom randomised, controlled open-label, platform adaptive trial

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the united kingdom randomised, controlled open-label, platform adaptive trial

<strong>Background: <br></strong>The safety, effectiveness and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, in patients in the community who are multiply-vaccinated and at increased risk of morbidity and mortality from COVID-19, has not been esta...

Description complète

Détails bibliographiques
Auteurs principaux: Butler, C, Hobbs, FDR, Gbinigie, O, Rahman, NM, Hayward, G, Richards, D, Dorward, J, Lowe, D, Standing, JF, Breuer, J, Khoo, S, Petrou, S, Hood, K, Nguyen-Van-Tam, JS, Patel, M, Saville, BR, Marion, J, Ogburn, E, Allen, J, Rutter, H, Francis, N, Thomas, N, Evans, P, Dobson, M, Madden, T-A, Holmes, J, Harris, V, Png, ME, Lown, M, van Hecke, O, Detry, M, Saunders, C, Fitzgerald, M, Berry, N, Mwandigha, L, Galal, U, Jani, B, Hart, N, Butler, D, Chalk, J, Lavallee, L, Hadley, E, Cureton, L, Benysek, M, Andersson, M, Coates, M, Barrett, S, Bateman, C, Davies, J, Raymundo-Wood, I
Format: Journal article
Langue:English
Publié: 2022

Documents similaires